Company intelligence / Profile preview

Cytopeia

Seattle, Washington, United States

Ownership: Private
Development stage: Other

Overview

Cytopeia was a biotechnology company specializing in the development of advanced flow cytometry and cell sorting instrumentation. The company was best known for its Influx cell sorter, a highly flexible and customizable platform used in high-end research applications. Cytopeia's technology focused on high-speed, high-purity cell separation, which is critical for various life science research fields including immunology and stem cell biology. In 2008, the company was acquired by BD Biosciences, a segment of Becton, Dickinson and Company, to enhance their portfolio of flow cytometry systems. The Influx technology continues to be a staple in the research community under the BD brand.

Modalities: Device
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Cytopeia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytopeia.

Explore the full profile